Sponsors (6)
The bill strengthens science-based GRAS standards, transparency, and FDA authority to improve food-safety assessments and public confidence, but does so at the cost of higher compliance burdens, fees, potential market disruptions and slower product entry that could raise prices and deter smaller firms.
Consumers (including children and pregnant women) face lower risk from harmful food ingredients because GRAS determinations now require stronger scientific evidence, consideration of cumulative exposures, and periodic reassessments.
Members of the public gain greater transparency and ability to review GRAS decisions because FDA must post GRAS notices, underlying data, written determinations and revocations and provide a public comment period.
Manufacturers, petitioners, and regulators get clearer regulatory standards, definitions (e.g., carcinogenicity, reproductive toxicity, food-contact substance), and updated fee rules, which should increase regulatory certainty, clarify expectations for safety submissions, and help align fee recovery with review costs.
Small and midsize food manufacturers will face substantially higher compliance costs (expert reviews, new studies, expanded data packages and recurring reassessments), which could be passed to consumers or drive some firms out of the market.
New ingredient introductions and product launches may be delayed because companies must await FDA review ('not to object') and face statutory review timelines (180 days plus possible extension), slowing market entry and innovation.
Reassessment and possible revocation of prior GRAS no‑objection determinations could force reformulation or removal of ingredients, disrupting product availability and imposing one-time reformulation costs on manufacturers (and indirectly on consumers).
Based on analysis of 6 sections of legislative text.
Tightens GRAS standards, creates a formal FDA GRAS notice/review process, mandates periodic safety reassessments, and adds fee recovery for notices and reassessments.
Revises federal food-safety law to tighten and clarify how a substance is judged "generally recognized as safe" (GRAS). The bill removes informal GRAS treatment embedded in the food-additive definition, establishes a statutory GRAS definition tied to qualified scientific experts and specific evidentiary standards, and creates a formal FDA notice-and-review process before industry may rely on a GRAS determination for new uses or new substances. Requires FDA to perform rolling safety reassessments of substances (at least 10 substance-classes every three years), gives the agency authority to require updated safety data and to revoke earlier no-objection letters, and expands user fees so FDA recovers full costs for GRAS notices and reassessment activities. The measure also adds new statutory definitions and updates fee baseline years; it authorizes appropriations to run the new review and reassessment functions.
Official title: To amend the Federal Food, Drug, and Cosmetic Act to require notification to the Food and Drug Administration prior to use of substances as generally recognized as safe, reassessment of the safety of certain substances marketed as generally recognized as safe, provide resources for reviews and reassessments, and for other purposes.
Introduced August 12, 2025 by Frank Pallone · Last progress August 12, 2025